Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis

Nature Reviews Nephrology

Volumn 8, Issue 3, 2012, Pages 141-150

  Ortiz, Alberto ^a   Massy, Ziad A ^b   Fliser, Danilo ^c   Lindholm, Bengt ^d   Wiecek, Andrzej ^e   Martínez Castelao, Alberto ^f   Covic, Adrian ^g   Goldsmith, David ^h   Süleymanlar, Gültekin ⁱ   London, Gérard M ^j   Zoccali, Carmine ^k  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c SAARLAND UNIVERSITY   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ AKDENIZ UNIVERSITY   (Turkey)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k CNR   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALKALINE PHOSPHATASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM; CD14 ANTIGEN; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FETUIN A; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 23; GELSOLIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MANNOSE BINDING LECTIN; MYELOPEROXIDASE; OSTEOGENIC PROTEIN 1; OSTEOPONTIN; PARATHYROID HORMONE; PENTRAXIN 3; PHOSPHATE; SCATTER FACTOR; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; FIBRINOGEN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; KIDNEY FAILURE; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW;

BIOLOGICAL MARKERS; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; WORLD HEALTH;

EID: 84857786422     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.170     Document Type: Review

References (97)

1. Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847 (1998). (Pubitemid 28213628)
2. D'Agostino, R. B. et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am. Heart J. 139, 272-281 (2000).
3. Cook, N. R. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115, 928-935 (2007). (Pubitemid 46294733)
4. Khan, I. H. et al. Influence of coexisting disease on survival on renal-replacement therapy. Lancet 341, 415-418 (1993). (Pubitemid 23048156)
5. Granger, C. B. et al. Do we need to adjudicate major clinical events? Clin. Trials 5, 56-60 (2008). (Pubitemid 351412373)
6. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
7. Tripepi, G., Jager, K. J., Dekker, F. W. & Zoccali, C. Testing for causality and prognosis: etiological and prognostic models. Kidney Int. 74, 1512-1515 (2008).
8. Manolio, T. Novel risk markers and clinical practice. N. Engl. J. Med. 349, 1587-1589 (2003). (Pubitemid 37288564)
9. Tripepi, G., Jager, K. J., Dekker, F. W. & Zoccali, C. Statistical methods for the assessment of prognostic biomarkers (Part I): discrimination. Nephrol. Dial. Transplant. 25, 1399-1401 (2010).
10. Knaus, W. A., Zimmerman, J. E., Wagner, D. P., Draper, E. A. & Lawrence, D. E. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit. Care Med. 9, 591-597 (1981).
11. Wilson, P. W. et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ. Cardiovasc. Qual. Outcomes 1, 92-97 (2008).
12. Shah, T. et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int. J. Epidemiol. 38, 217-231 (2009).
13. Ridker, P. M. et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
14. Nanchen, D. et al. Public health impact of statin prescribing strategies based on JUPITER. Prev. Med. 52, 159-163 (2011).
15. Wanner, C. et al. for the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248 (2005). (Pubitemid 41058323)
16. Fellström, B. C. et al. for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407 (2009).
17. Lindner, A., Charra, B., Sherrard, D. J. & Scribner, B. H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N. Engl. J. Med. 290, 697-701 (1974).
18. Brancaccio, D., Bellasi, A., Cozzolino, M., Galassi, A. & Gallieni, M. Arterial accelerated aging in dialysis patients: the clinical impact of vascular calcification. Curr. Vasc. Pharmacol. 7, 374-380 (2009).
19. KDIGO. Chapter 1: Introduction and definition of CKD-MBD and the development of the guideline statements. Kidney Int. 76 (Suppl. 113), S3-S8 (2009).
20. Fouque, D. et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 73, 391-398 (2008). (Pubitemid 351186278)
21. Morena, M. et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J. Am. Soc. Nephrol. 17, 262-270 (2006).
22. Speer, G. et al. Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol. Dial. Transplant. 23, 3256-3262 (2008).
23. Mesquita, M. et al. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin. Chem. Lab. Med. 47, 339-346 (2009).
24. Sigrist, M. K., Levin, A., Er, L. & McIntyre, C. W. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol. Dial. Transplant. 24, 3157-3162 (2009).
25. Gutiérrez, O. M. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584-592 (2008).
26. Jean, G. et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 24, 2792-2796 (2009).
27. Hsu, H. J. & Wu, M. S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am. J. Med. Sci. 337, 116-122 (2009).
28. Olauson, H. et al. Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrol. Dial. Transplant. 25, 3033-3038 (2010).
29. Regidor, D. L. et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J. Am. Soc. Nephrol. 19, 2193-2203 (2008).
30. Beddhu, S., Baird, B., Ma, X., Cheung, A. K. & Greene, T. Serum alkaline phosphatase and mortality in hemodialysis patients. Clin. Nephrol. 74, 91-96 (2010).
31. Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T. & Wanner, C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 55, 648-658 (1999). (Pubitemid 29082891)
32. Yeun, J. Y., Levine, R. A., Mantadilok, V. & Kaysen, G. A. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 35, 469-476 (2000). (Pubitemid 30124077)
33. Stenvinkel, P. et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int. 62, 1791-1798 (2002). (Pubitemid 35286288)
34. de Mutsert, R. et al. and the NECOSAD Study Group. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol. Dial. Transplant. 23, 2957-2964 (2008).
35. Herselman, M., Esau, N., Kruger, J. M., Labadarios, D. & Moosa, M. R. Relationship between serum protein and mortality in adults on long-term hemodialysis: exhaustive review and meta-analysis. Nutrition 26, 10-32 (2010).
36. Grootendorst, D. C. et al. and The NECOSAD Study Group. Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients-no additional power for mortality prediction with high-sensitivity CRP. Nephrol. Dial. Transplant. 22, 3277-3284 (2007). (Pubitemid 350202555)
37. Hickman, P. E. et al. Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. Intern. Med. J. 39, 812-818 (2009).
38. Snaedal, S. et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am. J. Kidney Dis. 53, 1024-1033 (2009).
39. McGill, D., Talaulikar, G., Potter, J. M., Koerbin, G. & Hickman, P. E. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. Clin. Chim. Acta 411, 936-939 (2010).
40. Meuwese, C. L. et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are similarly associated with survival in haemodialysis patients. Nephrol. Dial. Transplant. 26, 1313-1318 (2011).
41. Zoccali, C., Tripepi, G. & Mallamaci, F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J. Am. Soc. Nephrol. 17, S169-S173 (2006). (Pubitemid 44865244)
42. Honda, H. et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am. J. Kidney Dis. 47, 139-148 (2006). (Pubitemid 41828276)
43. Pecoits-Filho, R., Bárány, P., Lindholm, B., Heimbürger, O. & Stenvinkel, P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol. Dial. Transplant. 17, 1684-1688 (2002). (Pubitemid 35012175)
44. Rao, M. et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 45, 324-333 (2005). (Pubitemid 40431059)
45. Panichi, V. et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol. Dial. Transplant. 19, 1154-1160 (2004). (Pubitemid 38628135)
46. Hermans, M. M. et al. for The Netherlands cooperative study on the adequacy of Dialysis (NECOSAD). Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 72, 202-207 (2007). (Pubitemid 47067382)
47. Bláha, V. et al. Circulating fetuin-A predicts early mortality in chronic hemodialysis patients. Clin. Biochem. 42, 996-1000 (2009).
48. Metry, G. et al. Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. Eur. J. Clin. Invest. 38, 804-811 (2008).
49. Pertosa, G. et al. Serum fetuin A in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis? Am. J. Kidney Dis. 53, 467-474 (2009).
50. Hamano, T. et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J. Am. Soc. Nephrol. 21, 1998-2007 (2010).
51. Wang, A. Y. & Lai, K. N. Use of cardiac biomarkers in end-stage renal disease. J. Am. Soc. Nephrol. 19, 1643-1652 (2008).
52. Apple, F. S., Murakami, M. M., Pearce, L. A. & Herzog, C. A. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 106, 2941-2945 (2002). (Pubitemid 35424746)
53. deFilippi, C. et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 290, 353-359 (2003).
54. Khan, N. A., Hemmelgarn, B. R., Tonelli, M., Thompson, C. R. & Levin, A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 112, 3088-3096 (2005). (Pubitemid 43113440)
55. Satyan, S., Light, R. P. & Agarwal, R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am. J. Kidney Dis. 50, 1009-1019 (2007). (Pubitemid 350122814)
56. Mallamaci, F. et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 40, 68-75 (2002). (Pubitemid 34701213)
57. Zoccali, C. et al. and the Creed Investigators. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J. Am. Soc. Nephrol. 12, 1508-1515 (2001). (Pubitemid 32666334)
58. Needham, D. M., Shufelt, K. A., Tomlinson, G., Scholey, J. W. & Newton, G. E. Troponin I and T levels in renal failure patients without acute coronary syndrome: a systematic review of the literature. Can. J. Cardiol. 20, 1212-1218 (2004). (Pubitemid 39545556)
59. Winkler, K. et al. for the German Diabetes and Dialysis Study Investigators. Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur. Heart J. 29, 2092-2099 (2008).
60. Kanwar, M. et al. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients. Am. J. Cardiol. 98, 1283-1287 (2006). (Pubitemid 44739920)
61. Petrovic, D. & Stojimirovic, B. B. Cardiac troponins: outcome predictors in hemodialysis patients. J. Artif. Organs 12, 258-263 (2009).
62. Jacobs, L. H. et al. Haemodialysis patients longitudinally assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and cardiac troponin I assays. Ann. Clin. Biochem. 46, 283-290 (2009).
63. Tate, J. R. et al. for the IFCC Working Group on Standardization of Troponin I. Standardisation of cardiac troponin I measurement: past and present. Pathology 42, 402-408 (2010).
64. Lee, D. S. & Tu, J. V. Are multiple biomarker testing strategies ready for prime time in heart failure? Circ. Heart Fail. 2, 387-388 (2009).
65. Troughton, R. W. et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126-1130 (2000). (Pubitemid 30172933)
66. Troughton, R. W., Lewis, L. K., Yandle, T. G., Pemberton, C. J. & Nicholls, M. G. B-type natriuretic peptides: looking to the future. Ann. Med. 43, 188-197 (2011).
67. Zoccali, C., Tripepi, G., Cutrupi, S., Pizzini, P. & Mallamaci, F. Low triiodothyronine: a new facet of inflammation in end-stage renal disease. J. Am. Soc. Nephrol. 16, 2789-2795 (2005).
68. Zoccali, C., Mallamaci, F., Tripepi, G., Cutrupi, S. & Pizzini, P. Low triiodothyronine and survival in end-stage renal disease. Kidney Int. 70, 523-528 (2006). (Pubitemid 44144206)
69. Carrero, J. J. et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J. Intern. Med. 262, 690-701 (2007). (Pubitemid 350135193)
70. Wiederkehr, M. R., Kalogiros, J. & Krapf, R. Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. Nephrol. Dial. Transplant. 19, 1190-1197 (2004). (Pubitemid 38628140)
71. Böger, R. H. et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119, 1592-1600 (2009).
72. Zoccali, C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J. Hypertens. 24, 611-619 (2006).
73. Zoccali, C. et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358, 2113-2117 (2001). (Pubitemid 34094901)
74. Kumagai, H. et al. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Am. J. Kidney Dis. 48, 797-805 (2006). (Pubitemid 44740047)
75. Aucella, F. et al. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. Atherosclerosis 207, 541-545 (2009).
76. Schulze, F., Schwedhelm, E., Maas, R. & Böger, R. H. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 831, 333 (2006). (Pubitemid 43155814)
77. Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000). (Pubitemid 30165206)
78. Tripepi, G., Mallamaci, F. & Zoccali, C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J. Am. Soc. Nephrol. 16 (Suppl. 1), S83-S88 (2005). (Pubitemid 41725091)
79. Wang, T. J. et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 355, 2631-2639 (2006). (Pubitemid 44969122)
80. Dunlay, S. M. et al. Prognostic value of biomarkers in heart failure: application of novel methods in the community. Circ. Heart Fail. 2, 393-400 (2009).
81. Melander, O. et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. J. Am. Med. Assoc. 302, 49-57 (2009).
82. Mallamaci, F., Tripepi, G., Cutrupi, S., Malatino, L. S. & Zoccali, C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int. 67, 2330-2337 (2005). (Pubitemid 41623394)
83. Carrero, J. J. et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 4, 110-118 (2009).
84. Tripepi, G. et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin. J. Am. Soc. Nephrol. 6, 1714-1721 (2011).
85. Goligorsky, M. S., Addabbo, F. & O'Riordan, E. Diagnostic potential of urine proteome: a broken mirror of renal diseases. J. Am. Soc. Nephrol. 18, 2233-2239 (2007). (Pubitemid 47203837)
86. Fliser, D. et al. Advances in urinary proteome analysis and biomarker discovery. J. Am. Soc. Nephrol. 18, 1057-1071 (2007). (Pubitemid 46536892)
87. Weissinger, E. M. et al. Proteomics: a novel tool to unravel the patho-physiology of uraemia. Nephrol. Dial. Transplant. 19, 3068-3077 (2004). (Pubitemid 40057630)
88. Weissinger, E. M. et al. Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment. Proteomics 6, 993-1000 (2006). (Pubitemid 43260223)
89. Folli, F. et al. Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation. PLoS ONE 5, e9923 (2010).
90. Lin, Y. P. et al. Comparative proteomic analysis of rat aorta in a subtotal nephrectomy model. Proteomics 10, 2429-2443 (2010).
91. Gallego-Delgado, J. et al. Proteomic analysis of early left ventricular hypertrophy secondary to hypertension: modulation by antihypertensive therapies. J. Am. Soc. Nephrol. 17, S159-S164 (2006). (Pubitemid 44865242)
92. Delles, C. et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J. Hypertens. 28, 2316-2322 (2010).
93. Schiffer, E. et al. on behalf of the European Uremic Toxin Work Group (EUTox). Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. J. Hypertens. 29, 783-790 (2011).
94. Marshall, J. et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J. Proteome Res. 2, 361-372 (2003). (Pubitemid 36988415)
95. Thongboonkerd, V. Practical points in urinary proteomics. J. Proteome Res. 6, 3881-3890 (2007). (Pubitemid 350032551)
96. Mallamaci, F. et al. on behalf of the CREED Investigators. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 59, 1599-1606 (2001).
97. Isakowa, T., Gutiérrez, O. M. & Wolf, M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int. 76, 705-716 (2009).